Company intelligence / Profile preview

MySense AI

London, England, United Kingdommysense.ai ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Clinical evaluations at two NHS trusts have shown that the use of the MySense system led to a significant reduction in unplanned hospital admissions—up to 46%—and substantial cost savings per patient. The technology enables early detection of health deterioration by continuously analyzing data from multiple sensors and wearables placed in patients’ homes. This allows for timely interventions that help vulnerable individuals remain independent for longer while reducing healthcare costs.

Therapeutic areas: OtherEndocrinologyNeurology
Modalities: DeviceNon-pharmacological therapy (AI-driven monitoring platform with sensors and wearables)
Industry: Digital Health Medical Devices

Partnerships

National Health Service Trusts in the UKlocal authoritiesprivate healthcare organizations

Beyond the preview

Go deeper on MySense AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MySense AI.

Explore the full profile